Online inquiry

IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2123MR)

This product GTTS-WQ2123MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2123MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2077MR IVTScrip™ mRNA-Anti-IL17A, AIN457(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AIN457
GTTS-WQ4875MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ1008MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ14148MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ8267MR IVTScrip™ mRNA-Anti-GHR, HM10560A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HM10560A
GTTS-WQ6863MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA DX-2930
GTTS-WQ5396MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ9696MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64304500
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.